CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

BioSpace
Original article

AI drug hunter Enveda raises $311M for late-stage obesity, inflammatory disease push

Positive
AI Analysis

Summary

Enveda raised $311 million in funding, bringing total capital raised to $845 million over six years, to advance late-stage obesity and inflammatory disease programs with plans toward a future IPO.

Importance:6/10
Sentiment:
0.70
fundingobesityinflammatory diseaselate-stageIPO plansAI drug discovery

Read the original article

Published by BioSpace on September 23, 2026 2:31 PM

Read Original